mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant
Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However, vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
eLife Sciences Publications Ltd
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f03f1cad0695471492d26dc7d9bac0ad |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f03f1cad0695471492d26dc7d9bac0ad |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f03f1cad0695471492d26dc7d9bac0ad2021-11-29T12:11:43ZmRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant10.7554/eLife.693752050-084Xe69375https://doaj.org/article/f03f1cad0695471492d26dc7d9bac0ad2021-09-01T00:00:00Zhttps://elifesciences.org/articles/69375https://doaj.org/toc/2050-084XAge is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However, vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials. We determined the serological and cellular response to spike protein in 100 people aged 80–96 years at 2 weeks after the second vaccination with the Pfizer BNT162b2 mRNA vaccine. Antibody responses were seen in every donor with high titers in 98%. Spike-specific cellular immune responses were detectable in only 63% and correlated with humoral response. Previous SARS-CoV-2 infection substantially increased antibody responses after one vaccine and antibody and cellular responses remained 28-fold and 3-fold higher, respectively, after dual vaccination. Post-vaccine sera mediated strong neutralization of live Victoria infection and although neutralization titers were reduced 14-fold against the P.1 variant first discovered in Brazil they remained largely effective. These data demonstrate that the mRNA vaccine platform delivers strong humoral immunity in people up to 96 years of age and retains broad efficacy against the P.1 variant of concern.Helen ParryGokhan TutRachel BrutonSian FaustiniChristine StephensPhilip SaundersChristopher BentleyKatherine HilyardKevin BrownGayatri AmirthalingamSue CharltonStephanie LeungEmily ChiplinNaomi S CoombesKevin R BewleyElizabeth J PennCathy RoweAshley OtterRosie WattsSilvia D'ArcangeloBassam HallisAndrew MakinAlex RichterJianmin ZuoPaul MosseLife Sciences Publications LtdarticleCOVID-19vaccinationimmunosenescenceMedicineRScienceQBiology (General)QH301-705.5ENeLife, Vol 10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
COVID-19 vaccination immunosenescence Medicine R Science Q Biology (General) QH301-705.5 |
| spellingShingle |
COVID-19 vaccination immunosenescence Medicine R Science Q Biology (General) QH301-705.5 Helen Parry Gokhan Tut Rachel Bruton Sian Faustini Christine Stephens Philip Saunders Christopher Bentley Katherine Hilyard Kevin Brown Gayatri Amirthalingam Sue Charlton Stephanie Leung Emily Chiplin Naomi S Coombes Kevin R Bewley Elizabeth J Penn Cathy Rowe Ashley Otter Rosie Watts Silvia D'Arcangelo Bassam Hallis Andrew Makin Alex Richter Jianmin Zuo Paul Moss mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant |
| description |
Age is the major risk factor for mortality after SARS-CoV-2 infection and older people have received priority consideration for COVID-19 vaccination. However, vaccine responses are often suboptimal in this age group and few people over the age of 80 years were included in vaccine registration trials. We determined the serological and cellular response to spike protein in 100 people aged 80–96 years at 2 weeks after the second vaccination with the Pfizer BNT162b2 mRNA vaccine. Antibody responses were seen in every donor with high titers in 98%. Spike-specific cellular immune responses were detectable in only 63% and correlated with humoral response. Previous SARS-CoV-2 infection substantially increased antibody responses after one vaccine and antibody and cellular responses remained 28-fold and 3-fold higher, respectively, after dual vaccination. Post-vaccine sera mediated strong neutralization of live Victoria infection and although neutralization titers were reduced 14-fold against the P.1 variant first discovered in Brazil they remained largely effective. These data demonstrate that the mRNA vaccine platform delivers strong humoral immunity in people up to 96 years of age and retains broad efficacy against the P.1 variant of concern. |
| format |
article |
| author |
Helen Parry Gokhan Tut Rachel Bruton Sian Faustini Christine Stephens Philip Saunders Christopher Bentley Katherine Hilyard Kevin Brown Gayatri Amirthalingam Sue Charlton Stephanie Leung Emily Chiplin Naomi S Coombes Kevin R Bewley Elizabeth J Penn Cathy Rowe Ashley Otter Rosie Watts Silvia D'Arcangelo Bassam Hallis Andrew Makin Alex Richter Jianmin Zuo Paul Moss |
| author_facet |
Helen Parry Gokhan Tut Rachel Bruton Sian Faustini Christine Stephens Philip Saunders Christopher Bentley Katherine Hilyard Kevin Brown Gayatri Amirthalingam Sue Charlton Stephanie Leung Emily Chiplin Naomi S Coombes Kevin R Bewley Elizabeth J Penn Cathy Rowe Ashley Otter Rosie Watts Silvia D'Arcangelo Bassam Hallis Andrew Makin Alex Richter Jianmin Zuo Paul Moss |
| author_sort |
Helen Parry |
| title |
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant |
| title_short |
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant |
| title_full |
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant |
| title_fullStr |
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant |
| title_full_unstemmed |
mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant |
| title_sort |
mrna vaccination in people over 80 years of age induces strong humoral immune responses against sars-cov-2 with cross neutralization of p.1 brazilian variant |
| publisher |
eLife Sciences Publications Ltd |
| publishDate |
2021 |
| url |
https://doaj.org/article/f03f1cad0695471492d26dc7d9bac0ad |
| work_keys_str_mv |
AT helenparry mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT gokhantut mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT rachelbruton mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT sianfaustini mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT christinestephens mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT philipsaunders mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT christopherbentley mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT katherinehilyard mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT kevinbrown mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT gayatriamirthalingam mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT suecharlton mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT stephanieleung mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT emilychiplin mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT naomiscoombes mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT kevinrbewley mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT elizabethjpenn mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT cathyrowe mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT ashleyotter mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT rosiewatts mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT silviadarcangelo mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT bassamhallis mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT andrewmakin mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT alexrichter mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT jianminzuo mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant AT paulmoss mrnavaccinationinpeopleover80yearsofageinducesstronghumoralimmuneresponsesagainstsarscov2withcrossneutralizationofp1brazilianvariant |
| _version_ |
1718407439600058368 |